1Q26 Earnings: Where Street Estimates Are Too Low And Who Should Beat

Merck is described as Very Attractive, with 20% ROIC and a valuation around $120/share, supported by strong economic earnings. The article argues that GAAP and Street Earnings understate profitability, with 1Q26 Street EPS estimated to be understated by $3.29/share, implying a meaningful chance of beating consensus. The message is constructive for MRK, but it is primarily an analytical valuation/earnings call rather than a new company event.

Analysis

The market’s error here is likely not just underestimating next quarter, but mispricing the durability of earnings power. If Core Earnings are stripping out a large volume of “one-time” charges, then reported EPS is systematically lagging the economic run-rate, which usually creates a delayed re-rating once investors stop treating every period as transitory noise. For a company already generating high teens/20% ROIC, even a modest multiple expansion can matter more than a near-term beat because the equity is being valued off a depressed earnings base rather than normalized cash generation.

The second-order implication is relative positioning within large-cap healthcare: a durable beat-and-raise profile in a defensive name typically pulls capital out of lower-quality pharma peers and into the best balance-sheet/earnings-quality compounders. That can pressure competitors with less transparent earnings or heavier pipeline dependence, especially if MRK proves the consensus is persistently too low by a large margin. The hidden risk is that investors may not reward the beat if they believe the uplift is driven by accounting normalization rather than true acceleration in commercial momentum.

Catalyst timing likely clusters around the next print and the subsequent guidance reset, with the key question being whether management reinforces the higher earnings base or leaves room for skepticism. The main reversal risks are patent/launch timing slippage, an adverse shift in payer or litigation headlines, or a sudden rise in R&D/SG&A that narrows the gap between Core and Street. Over a 3-6 month horizon, the setup favors a re-rating if the company can deliver one or two clean beats without incremental controversy.

Key Decisions for Investors

• Go long MRK into the next earnings window with a 1-2 quarter horizon; the setup favors a beat-and-raise re-rating if the market is still anchoring to understated Street EPS.
• Buy MRK call spreads 3-6 months out to express upside on multiple expansion while limiting downside if the market discounts the beat as accounting-driven noise.
• Pair long MRK / short a lower-quality large-cap pharma peer with more volatile earnings quality; the trade benefits if investors rotate toward transparent ROIC and away from consensus disappointment risk.
• Use any post-print dip to add to MRK rather than chase strength, since the highest expected value entry is likely after the first round of skepticism fades.
• Trim if management fails to translate the earnings quality story into raised forward guidance; without a guide-up, the stock can stall even after a clean beat.